Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s stock price traded down 7.3% during trading on Tuesday. The stock traded as low as $17.25 and last traded at $17.2030. Approximately 5,529,756 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 22,187,676 shares. The stock had previously closed at $18.56.
Hims & Hers Health News Summary
Investors following HIMS have been watching these news items:
- Positive Sentiment: Hims & Hers launched Peptides+, initially offering five treatments—including sermorelin, glutathione and NAD+—with guidance from licensed medical providers. The expansion could open a new service category and broaden the company’s healthcare platform. CNBC coverage of Peptides+
- Neutral Sentiment: The initial peptide treatments are compounded and are not FDA-approved; Hims & Hers acknowledged that more research is needed on their efficacy. That uncertainty could limit adoption or bring regulatory and reputational risks, offsetting the potential from the expansion. Fierce Healthcare coverage of peptide expansion
- Negative Sentiment: Two insiders sold shares: CFO Oluyemi Okupe sold 3,518, while Deborah Autor sold 23,828. Both transactions were made under pre-arranged Rule 10b5-1 plans, which may make them less informative as signals of current views, though insider sales can still concern investors. Insider transaction report
Analyst Upgrades and Downgrades
Several analysts have issued reports on HIMS shares. Morgan Stanley cut their target price on shares of Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 10th. Deutsche Bank raised their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. started coverage on Hims & Hers Health in a report on Friday, September 11th. They set a “neutral” rating and a $32.00 price target on the stock. TD Cowen upped their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $31.53.
Get Our Latest Analysis on Hims & Hers Health
Hims & Hers Health Trading Down 6.0%
The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.84 and a current ratio of 0.92. The stock has a market cap of $3.76 billion, a price-to-earnings ratio of -19.30 and a beta of 2.53. The company’s 50 day simple moving average is $27.00 and its two-hundred day simple moving average is $26.54.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03). Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. The company had revenue of $890.37 million for the quarter, compared to analyst estimates of $893.13 million. During the same period last year, the business earned $0.06 EPS. The company’s quarterly revenue was up 48.6% on a year-over-year basis. Research analysts expect that Hims & Hers Health, Inc. will post -0.21 EPS for the current fiscal year.
Insider Transactions at Hims & Hers Health
In related news, CFO Oluyemi Okupe sold 29,277 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $29.95, for a total value of $876,846.15. Following the completion of the sale, the chief financial officer owned 236,527 shares of the company’s stock, valued at approximately $7,083,983.65. The trade was a 11.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 23,828 shares of the stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $18.53, for a total value of $441,532.84. Following the completion of the transaction, the insider owned 48,961 shares in the company, valued at $907,247.33. This represents a 32.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 105,041 shares of company stock valued at $2,764,840. 11.76% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its position in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after purchasing an additional 2,877,550 shares during the period. Bank of New York Mellon Corp acquired a new position in Hims & Hers Health during the second quarter valued at approximately $46,220,000. Bienville Capital Management LLC bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $27,242,000. Southpoint Capital Advisors LP bought a new position in shares of Hims & Hers Health in the first quarter valued at approximately $10,380,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Hims & Hers Health in the second quarter worth $11,520,000. Institutional investors and hedge funds own 63.52% of the company’s stock.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.
Read More
- Five stocks we like better than Hims & Hers Health
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
